carindacillin carindacillin carindacillin (inn), also known as carbenicillin indanyl (usan), is a penicillin antibiotic. it is a prodrug of carbenicillin. carindacillinclinical dataahfs/drugs.cominternational drug namesroutes ofadministrationoralatc codej01ca05 (who) legal statuslegal status in general: ℞ (prescription only) identifiers iupac name (2s,5r,6r)-6-(amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicycloheptane-2-carboxylic acid cas number35531-88-5salt: 26605-69-6 ypubchem cid93184chemspider391995unii5v278481kesalt: 4oul81k2rt ychemblchembl1200991comptox dashboard (epa)dtxsid6048705 chemical and physical dataformulac26h26n2o6smolar mass494.56 g·mol−13d model (jsmol)interactive image smiles .o=c()4n5c(=o)(nc(=o)c(c1ccccc1)c(=o)oc2cc3c(cc2)ccc3)5sc4(c)c it is administered orally, as the sodium salt. it was formerly marketed in the united states by pfizer under the brand name geocillin. pfizer withdrew carindacillin from the u.s. market sometime after 2008. pharmacokinetics shortly after absorption via the small intestine, carindacillin is hydrolyzed into carbenicillin. carbenicillin acts by interfering with final cell wall synthesis in susceptible bacteria, including pseudomonas aeruginosa, escherichia coli, and some proteus. the most common adverse effects include nausea, bad taste, diarrhea, vomiting, flatulence, and glossitis. carindacillin was approved for use in adults in the treatment of prostatitis and urinary tract infections. dosing was between 2000 and 4000 mg daily, divided into equally spaced doses.